ODP196 Evaluation of effectiveness of vitamin E on nonalcoholic fatty liver disease in type 2 diabetic patients without advanced fibrosis

OBJECTIVE: To determine effectiveness of vitamin E on nonalcoholic fatty liver disease in type 2 diabetic patients without advanced fibrosis. BACKGROUND: Alcoholic hepatic steatosis is widely distributed worldwide, especially in industrialized countries, where the incidence of diabetes, metabolic syndrome and dyslipidemia are more common. All this fatty liver disease is more common in Western society. Most studies on hepatic steatosis have excluded patients with diabetes from which they call attention, given that this specific group of patients is affected to a large extent by this disease. Therefore, it is urgent to establish guidelines at the same level of solid evidence regarding the treatment of the EHGNA within the high risk populations as for the patients with DM-2. Material and methods: Quasi experimental study performed in Dos de Mayo National Hospital, Lima, Peru from August 2016 to January 2017. One experimental group received vitamin E at a dose of 400 IU in addition to conventional management and another control group with conventional management were formed. The study included 71 patients in each group of Dos de Mayo National Hospital. The development of the present study counted with approval of the ethics committee of Dos de Mayo National Hospital Both groups were submitted to calculation of liver fibrosis scores as part of the evaluation of fibrotic activity by means of Non-alcoholic fatty liver disease (NAFLD) score, liver ultrasound evaluation and measurement of TGP at the beginning and after 6 months. To compare concentrations of the NAFLD fibrosis score and TGP values within a same group, the Wilcoxon and Mann-Whitney U test was used to assess differences between the experimental and control group. To compare severity of fatty liver on ultrasound, Wilcoxon test was used. Also, we performed logistic regression analysis Results: The results showed that vitamin E was effective in reducing level of transaminases and severity of fatty liver on ultrasound statistically significant (Z=-4,727 and p<0. 05) not related to confounding variables. CONCLUSION: It is concluded that vitamin E at a dose of 400 IU is an effective intervention to control the progression of hepatopathy that can be quantified by means of the NAFLD score and to achieve a decrease in transaminase levels as well as an improvement in the ultrasound valuation after 6 months of follow-up in a defined group of diabetic patients recently diagnosed with NAFLD without significant fibrosis. Implications: One of the contributions of the present study is the importance of early intervention such as vitamine E in a diabetic population that does not have significant fibrosis in whom an early diagnosis and timely intervention can reverse or slow down the process Presentation: No date and time listed